Real‑life Cretan asthma registry focused on severe asthma: On behalf of ‘The Cretan registry of the use of Biologics in Severe Asthma’

Antoniou,Katerina M.; Bolaki,Maria; Karagiannis,Konstantinos; Trachalaki,Athina; Ierodiakonou,Despo; Stamatopoulou,Vagia; Chatzinikolaou,Charito; Mastrodimou,Semeli; Stamataki,Evangelia; Pitsidianakis,George; Lambiri,Irini; Mitrouska,Ioanna; Spandidos,Demetrios A.; Tzanakis,Nikolaos

doi:10.3892/etm.2021.10674

Real‑life Cretan asthma registry focused on severe asthma: On behalf of ‘The Cretan registry of the use of Biologics in Severe Asthma’

Authors:
- Katerina M. Antoniou
- Maria Bolaki
- Konstantinos Karagiannis
- Athina Trachalaki
- Despo Ierodiakonou
- Vagia Stamatopoulou
- Charito Chatzinikolaou
- Semeli Mastrodimou
- Evangelia Stamataki
- George Pitsidianakis
- Irini Lambiri
- Ioanna Mitrouska
- Demetrios A. Spandidos
- Nikolaos Tzanakis
View Affiliations

Affiliations: Laboratory of Molecular and Cellular Pneumonology, Department of Respiratory Medicine, School of Medicine, University Hospital of Heraklion, University of Crete, 71003 Heraklion, Greece, Department of Intensive Care Medicine, School of Medicine, University Hospital of Heraklion, University of Crete, 71003 Heraklion, Greece, Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece
Published online on: September 1, 2021 https://doi.org/10.3892/etm.2021.10674
Article Number: 1239

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Asthma diagnosis and management remains a challenging task for the medical community. The aim of the present study was to present the functional and inflammatory profiles of patients with difficult‑to‑treat asthma in a real‑life clinical setting referred to the specialized asthma clinic at the University Hospital of Heraklion. The registry included a cohort of 267 patients who were referred to the severe asthma clinic. Patients were assessed with emphasis on the history of allergies, nasal polyposis or other comorbidities. Blood testing for eosinophils counts and total and specific IgE, and pulmonary function tests were performed at baseline. The median age of patients with asthma was 55 years old, 68.5% were women and 58.3% were never smokers. The vast majority presented with late onset asthma (75.7%), whereas eight (3%) patients were on oral corticosteroids. The median number of exacerbations during the last 12 months was 1 (0‑3). Furthermore, 50.7% of patients had a positive serum allergy test, the median eosinophil count was 300 (188‑508.5) cells/µl of blood and median total IgE level was 117.5 (29.4‑360.5) IU/ml. Patients were retrospectively grouped in the following categories: Group 1, mild‑moderate asthma; group 2, patients prescribed a step 4 or 5 asthma therapy according to Global Initiative for Asthma; and group 3, patients on biologic agents. Group 1 had significantly higher FEV1% than groups 2 and 3 (93.4 vs. 79.9 and 79.4%, respectively; P<0.001). Finally, the median Asthma Control Questionnaire 7 (ACQ7) score was 1.14, with patients from groups 2 and 3 presenting higher ACQ7 scores compared with group 1 patients as expected (1.1 and 2.1 vs. 0.7, respectively; P<0.001). To the best of our knowledge, this was the first real‑life asthma study in Crete that demonstrated that severe asthmatics predominantly have late‑onset asthma with airflow obstruction and uncontrolled symptoms.

View Figures

View References

1	Global Initiative for Asthma: 2021 GINA Report, Global Strategy for Asthma Management and Prevention. GINA, Fontana, 2021. https://ginasthma.org/gina-reports.
2	Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 43:343–373. 2014.PubMed/NCBI View Article : Google Scholar
3	Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, Gaga M, Kellermeyer L, Khurana S, Knight S, et al: Management of severe asthma: A European respiratory society/American thoracic society guideline. Eur Respir J. 55(1900588)2020.PubMed/NCBI View Article : Google Scholar
4	Selroos O, Kupczyk M, Kuna P, Łacwik P, Bousquet J, Brennan D, Palkonen S, Contreras J, FitzGerald M, Hedlin G, et al: National and regional asthma programmes in Europe. Eur Respir Rev. 24:474–483. 2015.PubMed/NCBI View Article : Google Scholar
5	MacDonald KM, Kavati A, Ortiz B, Alhossan A, Lee CS and Abraham I: Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: Systematic review of 42 studies published 2008-2018. Expert Rev Clin Immunol. 15:553–569. 2019.PubMed/NCBI View Article : Google Scholar
6	Pelaia C, Calabrese C, Terracciano R, de Blasio F, Vatrella A and Pelaia G: Omalizumab, the first available antibody for biological treatment of severe asthma: More than a decade of real-life effectiveness. Ther Adv Respir Dis. 12(1753466618810192)2018.PubMed/NCBI View Article : Google Scholar
7	Deeks ED: Mepolizumab: A review in eosinophilic asthma. BioDrugs. 30:361–370. 2016.PubMed/NCBI View Article : Google Scholar
8	Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, Harrington J, Hew M, Kritikos V, Radhakrishna N, et al: Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 55(1902420)2020.PubMed/NCBI View Article : Google Scholar
9	Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Baros M, Buhl R, Howarth P, Alberts F, et al: Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 143:1742–1751.e7. 2019.PubMed/NCBI View Article : Google Scholar
10	Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML and Bel EH: The prevalence of severe refractory asthma. J Allergy Clin Immunol. 135:896–902. 2015.PubMed/NCBI View Article : Google Scholar
11	von Bülow A, Kriegbaum M, Backer V and Porsbjerg C: The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract. 2:759–767. 2014.PubMed/NCBI View Article : Google Scholar
12	ISAR Study Group. International severe asthma registry: Mission statement. Chest. 157:805–814. 2020.PubMed/NCBI View Article : Google Scholar
13	Zervas E, Loukides S, Kostikas K, Bakakaos P, Tzortzaki E and Gaga M: On Behalf of Asthma Working Group of Hellenic Thoracic Society. Asthma and asthma-like symptoms in Greece. The Greece asthma national prevalence survey. Eur Respir J. 40 (Suppl 56)(P3936)2012.
14	Kourlaba G, Bakakos P, Loukides S, Vellopoulou K, Solakidi A and Maniadakis N: The self-reported prevalence and disease burden of asthma in Greece. J Asthma. 56:478–497. 2019.PubMed/NCBI View Article : Google Scholar
15	Juniper EF, O'byrne PM, Guyatt GH, Ferrie PJ and King DR: Development and validation of a questionnaire to measure asthma control. Eur Respir J. 14:902–907. 1999.PubMed/NCBI View Article : Google Scholar
16	Khusial RJ, Honkoop PJ, van der Meer V, Snoeck-Stroband JB and Sont JK: Validation of online asthma control questionnaire and asthma quality of life questionnaire. ERJ Open Res. 6:00289–2019. 2020.PubMed/NCBI View Article : Google Scholar
17	Zervas E, Samitas K, Papaioannou AI, Bakakos P, Loukides S and Gaga M: An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ Open Res. 4:00125–2017. 2018.PubMed/NCBI View Article : Google Scholar
18	Papi A, Saetta M and Fabbri L: Severe asthma: Phenotyping to endotyping or vice versa? Eur Respir J. 49(1700053)2017.PubMed/NCBI View Article : Google Scholar
19	Vellopoulou K, Bakakos P, Loukides S, Maniadakis N and Kourlaba G: The Economic burden of asthma in Greece: A cross-sectional study. Appl Health Econ Health Policy. 17:629–640. 2019.PubMed/NCBI View Article : Google Scholar
20	Souliotis K, Kousoulakou H, Hillas G, Bakakos P, Toumbis M, Loukides S and Vassilakopoulos T: Direct and indirect costs of asthma management in Greece: An expert panel approach. Front Public Health. 5(67)2017.PubMed/NCBI View Article : Google Scholar
21	Wenzel SE, Brillhart S and Nowack K: An invisible disease: Severe asthma is more than just ‘bad asthma’. Eur Respir J. 50(1701109)2017.PubMed/NCBI View Article : Google Scholar
22	van Bragt JJMH, Adcock IM, Bel EHD, Braunstahl GJ, ten Brinke A, Busby J, Canonica GW, Cao H, Chung KF, Csoma Z, et al: Characteristics and treatment regimens across ERS SHARP severe asthma registries. Eur Respir J. 55(1901163)2020.PubMed/NCBI View Article : Google Scholar
23	Sá-Sousa A, Fonseca JA, Pereira AM, Ferreira A, Arrobas A, Mendes A, Drummond M, Videira W, Costa T, Farinha P, et al: The portuguese severe asthma registry: Development, features, and data sharing policies. Biomed Res Int. 2018(1495039)2018.PubMed/NCBI View Article : Google Scholar
24	Taube C, Bramlage P, Hofer A and Anderson D: Prevalence of oral corticosteroid use in the German severe asthma population. ERJ Open Res. 5:00092–2019. 2019.PubMed/NCBI View Article : Google Scholar
25	Bousquet J, Brusselle G, Buhl R, Busse WW, Cruz AA, Djukanovic R, Domingo C, Hanania NA, Humbert M, Menzies Gow A, et al: Care pathways for the selection of a biologic in severe asthma. Eur Respir J. 50(1701782)2017.PubMed/NCBI View Article : Google Scholar
26	AL-Jahdali H, Anwar A, AL-Harbi A, Baharoon S, Halwani R, Al Shimemeri A and Al-Muhsen S: Factors associated with patient visits to the emergency department for asthma therapy. BMC Pulm Med. 12(80)2012.PubMed/NCBI View Article : Google Scholar
27	Stensen L, Porsbjerg C, Sverrild A, Nybo Jensen B and Vibeke B: Managing asthma in the outpatient clinic: Is the diagnosis of asthma confirmed objectively according to guidelines? Eur Respir J. 40 (Suppl 56)(P2263)2012.
28	Assaf SM and Hanania NA: Biological treatments for severe asthma. Curr Opin Allergy Clin Immunol. 19:379–386. 2019.PubMed/NCBI View Article : Google Scholar
29	McGregor MC, Krings JG, Nair P and Castro M: Role of biologics in asthma. Am J Respir Crit Care Med. 199:433–445. 2019.PubMed/NCBI View Article : Google Scholar
30	Rabe KF: New biologics for severe asthma: What patients, what agents, what results, at what cost? Am J Respir Crit Care Med. 199:406–408. 2019.PubMed/NCBI View Article : Google Scholar
31	Pavord I, Bahmer T, Braido F, Cosío BG, Humbert M, Idzko M and Adamek L: Severe T2-high asthma in the biologics era: European experts' opinion. Eur Respir Rev. 28(190054)2019.PubMed/NCBI View Article : Google Scholar
32	Doroudchi A, Pathria M and Modena BD: Asthma biologics: Comparing trial designs, patient cohorts and study results. Ann Allergy Asthma Immunol. 124:44–56. 2020.PubMed/NCBI View Article : Google Scholar
33	Papaioannou AI, Fouka E, Papakosta D, Papiris S and Loukides S: Switching between biologics in severe asthma patients. When the first choice is not proven to be the best. Clin Exp Allergy. 51:221–227. 2021.PubMed/NCBI View Article : Google Scholar
34	Pepper AN, Hanania NA, Humbert M and Casale TB: How to assess effectiveness of biologics for asthma and what steps to take when there is not benefit. J Allergy Clin Immunol Pract. 9:1081–1088. 2021.PubMed/NCBI View Article : Google Scholar
35	Kallieri M, Zervas E, Katsoulis K, Fouka E, Porpodis K, Samitas K, Papaioannou AI, Kipourou M, Gaki E, Vittorakis S, et al: Mepolizumab in severe eosinophilic asthma: A 2-year follow-up in specialized asthma clinics in Greece: An interim analysis. Int Arch Allergy Immunol. 181:613–617. 2020.PubMed/NCBI View Article : Google Scholar